Chiron is an organ-on-chip (OoC) company possessing patent-protected technology for mechanically stimulating human cells, which was leveraged to develop an in-vitro joint model to study rheumatoid and osteoarthritis. chiron possesses a competitive advantage as the only OoC company able to provide mechanical stimulation while simultaneously monitoring cells under a microscope, offering access to extremely important information for drug development, cell therapies, as well as scientific discovery. Based on these unique features, chiron’s first product line is focused on recreating the human joint, specifically the knee. The beta version of chiron’s cartilage-, and synovial-membrane, on-chip devices are ready to begin selling to customers. Aside from selling one-time-use devices, chiron will also provide experimental services in house. The current lack of reliable models to study arthritis, as well as the sufficiently large global drug market associated (the rheumatoid arthritis drug market was $57.9 billion USD in 2019), makes customers within the field an interesting initial target segment, for the company. To support the first two years of development, chiron is soliciting an initial investment of 200.000€ by the end of 2022.

Dustin Dopsa
Carlo Alberto Paggi
Dustin Dopsa